News

  1. Anacor Pharmaceuticals Announces Positive Results From The Second Phase 3 Trial Of Tavaborole For Onychomycosis
    3/4/2013

    Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is a topical anti-fungal for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

  2. Sanofi And Regeneron Report Positive Proof-of-Concept Data For Dupilumab
    3/4/2013

    PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

  3. Portola And Lee's Pharmaceutical Enter Into Agreement To Expand Phase 3 APEX Study Of Betrixaban Into China
    1/29/2013

    Portola Pharmaceuticals, Inc. and Lee's Pharmaceutical (HK) Ltd. (HKSE: 0950) today announced an agreement to jointly expand the Phase 3 APEX study of betrixaban into China, with an option for Lee's to negotiate for the commercial rights to the drug in China.

  4. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, In Patients With Epilepsy
    12/3/2012

    Upsher-Smith Laboratories, Inc., (Upsher-Smith) announced that Phase I data for USL261 (intranasal midazolam) in patients with epilepsy were presented at the American Epilepsy Society Annual Meeting in San Diego, CA.

  5. ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
    9/21/2012

    ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced today that the U.S. Food & Drug Administration (FDA) has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20.

  6. Halozyme Presents Positive Data From Two Ultrafast Insulin Clinical Trials With Human Hyaluronidase Enzyme - rHuPH20 - At ADA 2012
    6/9/2012

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the multiple daily injection therapy and continuous subcutaneous insulin infusion markets.

  7. AstraZeneca And Amgen Announce Collaboration To Jointly Develop And Commercialise Clinical-Stage Inflammation Portfolio
    4/4/2012
    AstraZeneca and Amgen recently announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
  8. Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
    3/29/2012
    New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
  9. CROS NT Announces Further Expansion Into The UK Market
    1/11/2012
    CROS NT is starting the new year by announcing its expansion into the United Kingdom.
  10. Oxygen Biotherapeutics To Begin Clinical Study To Determine Efficacy Of Dermacyte® In Relieving Histamine Induced Pruritus
    1/10/2012
    Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study will begin later this month at St. John's Medical College Hospital in Bangalore, India.